ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Chiral Virus-Like Nanoplatform That Broadly Mediates Antibiotic Delivery to the Brain for Bacterial Meningitis Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Blood-brain barrier (BBB) preserves brain homeostasis yet restricts therapeutics; in bacterial meningitis, antibiotics' limited penetration impairs delivery to the parenchyma and cerebrospinal fluid, constraining efficacy and motivating strategies to overcome the barrier. To address this, we developed a chiral virus-mimicking mesoporous silica nanostructure (CVSN) functionalized with L-alanine for antibiotic delivery. It offers several distinct advantages: (1) nanoscale dimensions facilitating BBB transport; (2) virus-like morphology enhancing vascular accumulation and penetration, providing a foundation for passive targeting; (3) chiral surface modification conferring active recognition capacity for more efficient biological targeting; and (4) a mesoporous architecture that ensures high drug-loading efficiency and controlled release of drugs. Experimentally, it achieves efficient BBB penetration into the brain parenchyma and shows targeted delivery into microglia and astrocytes. Simulating the loading of cargoes by viruses, it ultimately improves the bioavailability and brain parenchyma and cerebrospinal fluid contents of various antibiotics with distinct physicochemical properties, antibacterial spectrum, and BBB penetration capacity, including cefoperazone, norfloxacin, levofloxacin and imipenem. It helps to treat meningitis induced by both Gram-negative bacteria (e.g., Escherichia coli) and Gram-positive bacteria (e.g., Staphylococcus aureus) and provides a promising avenue to overcome the limitations imposed by the BBB for CNS infections antibiotic therapy in clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.